Promising multicomponent influenza-COVID-19 vaccine candidates currently being evaluated in clinical trials may represent an important advancement in adult immunization strategy, and a meaningful opportunity to strengthen protection against two of the most consequential respiratory pathogens worldwide.
Abstract
Seasonal influenza and SARS-CoV-2 are respiratory viruses that represent a global health concern, causing substantial numbers of hospitalizations and mortality, particularly among high-risk groups, including infants and older adults. Together these associated respiratory diseases and related complications are among the leading causes of morbidity and mortality. Although effective vaccines are available for protection against influenza and COVID-19, vaccine uptake remains below the levels recommended by the World Health Organization (WHO). Increasing vaccination coverage is critical for protecting vulnerable populations and reducing strain on healthcare systems. To improve vaccine uptake, the WHO recommends co-administering influenza and COVID-19 vaccines when epidemiologically justified. A multicomponent vaccine approach in adults could go beyond the current co-administration approach, as it has the potential to streamline delivery, reduce missed vaccination opportunities, and enhance vaccine coverage among individuals at risk. This manuscript reviews the current evidence on multicomponent vaccination for protection against seasonal influenza and COVID-19. We summarize published literature on the potential public health impacts of a multicomponent vaccination approach, discuss associated challenges, and review multicomponent vaccines currently in development. The studies in this review highlight various potential benefits of a multicomponent approach, including simplified dosing, greater vaccination coverage, and reduced disease burden and costs. Healthcare workers expressed a preference for a combination vaccine over standalone influenza or COVID-19 vaccines, indicating a high likelihood of recommending it to patients. Consumers also showed strong interest. For multicomponent vaccination to succeed, key considerations include the optimal timing of administration and appropriate strain selection for both the influenza and SARS-CoV-2 viruses. Promising multicomponent influenza-COVID-19 vaccine candidates currently being evaluated in clinical trials may represent an important advancement in adult immunization strategy, and a meaningful opportunity to strengthen protection against two of the most consequential respiratory pathogens worldwide.
The findings highlight recent attitudes and barriers to influenza and COVID-19 vaccination among the FluSurvey cohort, which may inform approaches to improve vaccination coverage in the population.
L. Adams, C. Watson, R. E. Green et al.· medRxiv· 0 citations
COVID-19 vaccination in pregnancy, with or without influenza vaccine coadministration, was safe and well-tolerated by survey respondents and no new or worsening health problems were reported after coadministration of COVID-19 and influenza vaccines during pregnancy.
Sophie Tran, E. McClymont, S. Blitz et al.· Vaccine· 0 citations
INTRODUCTION
Individuals with Down syndrome are at increased risk for severe disease from acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, making them a priority group for COVID-19 vaccination. Data on vaccine uptake and factors associated with vaccination are needed to inform strategies to improve upta...
Nian Hui, T. Ding, Rees L. Lee et al.· Vaccine· 0 citations
This review provides an update on four vaccine-preventable respiratory infections that are particularly common or severe in older adults: coronavirus disease 2019 (COVID-19), respiratory syncytial virus (RSV) infection, seasonal influenza, and pneumococcal disease.
M. Paccalin, P. Loubet· Gériatrie et Psychologie Neu...· 0 citations
Findings highlight the need for robust and agile vaccine development, registration, and distribution infrastructures, as well as flexible response strategies adaptable to varying pandemic severity and transmissibility, and should consider adopting a comprehensive framework integrating health outcome metrics and the eco...
Sam Lovick, Malur Sudhanva, Alexander T. Kennedy et al.· Human Vaccines & Immunothera...· 0 citations
In Sweden, the implementation of LAIV is estimated to be cost-effective in 2-17-year-olds by reducing disease burden and healthcare costs in both children and the broader population.
P. Brodin, F. Wilczyński, Luca Ricci-Pacifici et al.· Infectious Disease and Thera...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.